1. Chan JY, et al. On the clinical implications of systemic and local immune responses in human angiosarcoma. NPJ Precision Oncology 2021;5(1):11.
2. Tan GF, …, Chan JY Bizarre giant cells in human angiosarcoma exhibit chemoresistance and confer poor survival outcomes. Cancer Science 2021;112(1):397-409.
3. Tan GF and Chan JY Towards precision oncology in angiosarcomas using next generation “omic” technologies. Oncotarget. 2021;12(19):1953-1955.
4. Chan JY, et al. Towards next generation biomarkers in natural killer/T-cell lymphoma. Life 2021;11(8):838.
5. Yang X, …, Chan JY Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population. BMC Cancer 2021;21(1):566.
6. Chang JW, …, Chan JY Genomic landscapes of acral melanomas in East Asia. Cancer Genomics & Proteomics 2021; 18(1): 83–92.
7. Liu S, …, Chan JY, et al. Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in Preclinical Models of Advanced Ovarian Cancer. Journal of Clinical Investigation 2021:145035.
8. Sun Y, …, Chan JY, et al. CREBBP cooperates with cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Letters 2021;S0304-3835(21)00438-9.
9. Chan JY, et al. Multi-omic analysis and immunoprofiling reveals distinct subtypes of human angiosarcoma. Journal of Clinical Investigation 2020;130(11):5833-5846.
10. Chan JY, et al. Multiple neoplasia in a patient with Gitelman syndrome harboring germline monoallelic MUTYH mutation. NPJ Genomic Medicine 2020;5:39.
11. Chan JY, et al. Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinoma. Liver Cancer International 2020; 1(1):25– 35.
12. Huang D, …, Chan JY, et al. Whole Genome Sequencing Reveals Potent Therapeutic Strategy for Monomorphic Epitheliotropic Intestinal T-cell Lymphoma. Blood Advances 2020;4(19):4769-4774.
13. Lim JQ, …, Chan JY, et al. Whole-genome Sequencing Identifies Responders to Pembrolizumab in Relapse/Refractory Natural-killer/T Cell Lymphoma. Leukemia 2020 Dec;34(12):3413-3419.
14. International NKTCL Working Group. A Genome-wide association study identifies two novel susceptibility loci for extranodal natural killer T-cell lymphoma. Lancet Oncology 2020;21(2):306-316.
15. Chan JY and Lim ST. Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. International Journal of Hematology 2018;107(4):413-419.
16. Chan JY, et al. Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma. Blood Cancer Journal 2018;8(11):111.
17. Chan JY, et al. Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Scientific Reports 2018;8(1):11959.
18. Tan J, …, Chan JY, et al. Genomic landscapes of breast fibroepithelial tumors. Nature Genetics 2015;47(11):1341-5.
19. Subramaniam MM, Chan JY, et al. Dedifferentiated liposarcoma with unusual Kaposiform morphology and whorl formation masquerading a Kaposi sarcoma: Diagnostically challenging case confirmed by cytogenetic and TP53 mutation analyses. Journal of Clinical Oncology 2013;31(7):e101-5.
20. Chan JY. On Genetic Information Uncertainty and the Mutator Phenotype in Cancer. Biosystems 2012;108(1-3):28–33.